Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

UHC Updates Rituximab Policy to Require Use of Biosimilars

From the College  |  October 19, 2020

As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.

ACR Comments Help Inform ICER Assessment of Treatments for Lupus Nephritis & Other Rheumatic Conditions

Mary Beth Nierengarten  |  October 19, 2020

The ACR submitted comments to the Institute for Clinical & Economic Review outlining key considerations that should inform independent assessment of the efficacy and cost-effectiveness of medical therapies for lupus nephritis.

RheumPAC Kicks Off November Matching Campaign

From the College  |  October 19, 2020

RheumPAC will once again conduct a matching campaign in November, coinciding with ACR Convergence 2020. During this time, all donations to RheumPAC will be amplified by leaders from the College, who will match various dollar amounts for each contribution. Additionally, many will donate a larger amount for first-time investors. Last year, matching funds contributed $91…

ACR Convergence 2020 Workshop Covers 2021 Practice Management & Coding Changes

Mary Beth Nierengarten  |  October 19, 2020

Attendees at the daylong workshop will learn about key evaluation and management code changes coming in 2021 that affect rheumatologists and rheumatology professionals.

Bring Quality Measures into Focus at ACR Convergence 2020

Vanessa Caceres  |  October 19, 2020

A panel of rheumatologists will provide updates on MACRA’s quality measure requirements and the ACR’s progress in quality measurement in rheumatology in a session at ACR Convergence 2020.

Pregnancy Complications in Patients with Lupus & APS

Keri Losavio  |  October 12, 2020

Pregnancy complications are common in lupus and antiphospholipid syndrome (APS), but can we predict and prevent them? The Rheumatology Research Foundation Memorial Lectureship to Honor Shaun Ruddy, MD, will review the predictors and mechanisms of pregnancy complications, as well as potential interventions for preventing pregnancy complications associated with lupus and APS. Watch for it on…

Lupus Nephritis: New Decade, New Approaches

Keri Losavio  |  October 12, 2020

This session at ACR Convergence will focus on early biomarkers for diagnostic and prognostic purposes, as well as the description of current treatment guidelines from multiple societies. The speakers will discuss the role of repeated biopsy to assess response and maintenance therapy, and describe some promising new therapies under development. Watch for it on Sunday,…

Pain in RA and OA: ACR Convergence 2020 Preview

Keri Losavio  |  October 12, 2020

Patients with RA and OA have joint pain, and pain is the primary reason patients seek care. The mechanisms responsible for the pain are now just beginning to be understood. This session, on Nov. 6, 4 p.m. EST, will cover the mechanisms responsible for the development of pain in both inflammatory and degenerative arthritis.

Racial Disparity in RA & OA: ACR Convergence 2020 Preview

Thomas R. Collins  |  October 12, 2020

Minority race/ethnicity are associated with more severe outcomes in OA and RA. Although African Americans have more symptomatic RA than whites, they are more likely to delay seeking care and initiating DMARDs and biologics. The session on Nov. 6, 3 p.m. EST, will review current outcomes data for RA and OA, including TKA, THA and…

Familial Patterns in Childhood- & Adult-Onset SLE

Kurt Ullman  |  October 12, 2020

A study examining familial patterns of systemic lupus erythematosus (SLE) found a greater decline in SLE recurrence rate by generation in childhood- than in adult-onset SLE, suggesting adult-onset SLE may be characterized by environmental risk factors.

  • « Previous Page
  • 1
  • …
  • 179
  • 180
  • 181
  • 182
  • 183
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences